Login to Your Account



(Not) just the FAKs: Pfizer, Merck, Verastem 'stroma' combo chord in ovarian cancer trial

By Randy Osborne
Staff Writer

Thursday, March 3, 2016

Having taken "a little bit of time to dig out" from last September's setback with VS-6063, Verastem Inc. CEO Robert Forrester said the firm "made a point of talking with the outside world" about the potential of FAK inhibitors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription